1,282
Views
9
CrossRef citations to date
0
Altmetric
Malignant Lymphoma

The role of follicular T helper cells in patients with malignant lymphoid disease

, , , , , & show all

References

  • Fazilleau N, Mark L, McHeyzer-Williams LJ, et al. Follicular helper T cells: lineage and location. Immunity. 2009;30(3):324–35. doi: 10.1016/j.immuni.2009.03.003
  • Rodriguez-Pinilla SM, Atienza L, Murillo C, et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol. 2008;32(12):1787–99. doi: 10.1097/PAS.0b013e31817f123e
  • Nurieva RI, Chung Y. Understanding the development and function of T follicular helper cells. Cell Mol Immunol. 2010;7(3):190–7. doi: 10.1038/cmi.2010.24
  • Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154–CD40 interactions. J Clin Invest. 2003;112(10):1506–20. doi: 10.1172/JCI200319301
  • Zhu C, Ma J, Liu Y, et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocr Metab. 2012;97(3):943–50. doi: 10.1210/jc.2011-2003
  • Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010;62(1):234–44. doi: 10.1002/art.25032
  • Bosisio FM, Cerroni L. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Am J Dermatopathol. 2015;37(2):115–21. doi: 10.1097/DAD.0000000000000258
  • Claman HN, Chaperon EA, Triplett RF. Thymus-marrow cell combinations. Synergism in antibody production. Proc Soc Exp Biol Med. 1966;122(4):1167–71. doi: 10.3181/00379727-122-31353
  • Miller JF, Mitchell GF. Cell to cell interaction in the immune response: I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. J Exp Med. 1968;128(4):801–20. doi: 10.1084/jem.128.4.801
  • Schaerli P, Willimann K, Lang AB, et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000;192(11):1553–62. doi: 10.1084/jem.192.11.1553
  • Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192(11):1545–52. doi: 10.1084/jem.192.11.1545
  • McHeyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. Science. 1995;268(5207):106–11. doi: 10.1126/science.7535476
  • Linterman MA, Vinuesa CG. T follicular helper cells during immunity and tolerance. Prog Mol Biol Transl Sci. 2010;92:207–48. doi: 10.1016/S1877-1173(10)92009-7
  • Bentebibel S-E, Schmitt N, Banchereau J, et al. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci USA. 2011;108(33):E488–97. doi: 10.1073/pnas.1100898108
  • Ferretti E, Bertolotto M, Deaglio S, et al. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia. 2011;25(8):1268–77. doi: 10.1038/leu.2011.88
  • Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011;34(6):932–46. doi: 10.1016/j.immuni.2011.03.023
  • Bertino SA, Craft J. Roquin paralogs add a new dimension to ICOS regulation. Immunity. 2013;38(4):624–6. doi: 10.1016/j.immuni.2013.03.007
  • Akiba H, Takeda K, Kojima Y, et al. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol. 2005;175(4):2340–8. doi: 10.4049/jimmunol.175.4.2340
  • Hams E, McCarron MJ, Amu S, et al. Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. J Immunol. 2011;186(10):5648–55. doi: 10.4049/jimmunol.1003161
  • Haymaker C, Wu R, Bernatchez C, et al. PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint. Oncoimmunology. 2012;1(5):735–8. doi: 10.4161/onci.20823
  • Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi: 10.1146/annurev.immunol.26.021607.090331
  • Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol. 2010;22(1):7–12. doi: 10.1093/intimm/dxp112
  • Eto D, Lao C, DiToro D, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4T cell (Tfh) differentiation. PloS One. 2011;6(3):e17739–00. doi: 10.1371/journal.pone.0017739
  • Pelletier N, McHeyzer-Williams LJ, Wong KA, et al. Plasma cells negatively regulate the follicular helper T cell program. Nat Immunol. 2010;11(12):1110–8. doi: 10.1038/ni.1954
  • Cui Y, Guan Y, Liu W, et al. [The changes of circulating follicular regulatory T cells and follicular T helper cells in children immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(11):980–4.
  • Zhang Q, Bai H, Wang W. Increased percentages of T cells producing interleukin-21 in patients with immune thrombocytopenic purpura. Cell Biol Int. 2014;38(4):520–5. doi: 10.1002/cbin.10220
  • Grogg KL, Attygalle AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19(8):1101–7.
  • Battistella M, Beylot-Barry M, Bachelez H, et al. Primary cutaneous follicular helper T-cell lymphoma: a new subtype of cutaneous T-cell lymphoma reported in a series of 5 cases. Arch Dermatol. 2012;148(7):832–9. doi: 10.1001/archdermatol.2011.3269
  • Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83. doi: 10.1016/S1470-2045(16)30053-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.